Anticoagulation Monitoring

Clinics in Laboratory Medicine

Volumn 29, Issue 2, 2009, Pages 283-304

  Ng, Valerie L ^a  

^a ALAMEDA COUNTY MEDICAL CENTER   (United States)

Author keywords

Direct thrombin inhibitors; Heparin; Low molecular weight heparin; Non standardized coagulation testing; Reagent variability; Warfarin; Xa inhibitors

Indexed keywords

4 [(2 AMIDINO 1,2,3,4 TETRAHYDRO 7 ISOQUINOLINYLOXY)METHYL] 1 (4 PYRIDINYL) 4 PIPERIDINECARBOXYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DICOUMAROL; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRUDIN DERIVATIVE; HIRULOG; IDRAPARINUX; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLOOD CLOTTING TEST; CLINICAL LABORATORY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG STRUCTURE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; SELF EVALUATION;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; HEPARIN; HUMANS; WARFARIN;

EID: 68149180804     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.05.003     Document Type: Review

References (76)

1. Hirsh J., O'Donnell M., and Eikelboom J.W. Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116 5 (2007) 552-560
2. Gerotziafas G.T., and Samama M.M. Heterogeneity of synthetic factor Xa inhibitors. Curr Pharm Des 11 30 (2005) 3855-3876
3. Di Nisio M., Middeldorp S., and Buller H.R. Direct thrombin inhibitors. N Engl J Med 353 10 (2005) 1028-1040
4. Duxbury B.M., and Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost 7 4 (2001) 269-275
5. Wardrop D., and Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 141 6 (2008) 757-763
6. Link K.P. The discovery of dicumarol and its sequels. Circulation 19 1 (1959) 97-107
7. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 141S-159S
8. Hirsh J., Guyatt G., Albers G.W., et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 71S-109S
9. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 454S-545S
10. Salem D.N., O'Gara P.T., Madias C., et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 133 6 Suppl (2008) 593S-629S
11. Leech B.F., and Carter C.J. Falsely elevated INR results due to the sensitivity of a thromboplastin reagent to heparin. Am J Clin Pathol 109 6 (1998) 764-768
12. Takeuchi F., McGinnis R., Bourgeois S., et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5 3 (2009) e1000433. http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1000433 Accessed July 13, 2009.
13. Lassen J.F., Brandslund I., and Antonsen S. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin Chem 41 3 (1995) 444-447
14. Adcock D., Brien W., Duff S., et al. Procedures for validation of INR and local calibration of PT/INR systems; approved guideline (2005), Clinical and Laboratory Standards Institute, Wayne (PA) H54-A
15. Ng V.L., Levin J., Corash L., et al. Failure of the international normalized ratio to generate consistent results within a local medical community. Am J Clin Pathol 99 6 (1993) 689-694
16. Ng V.L., Valdes-Camin R., Gottfried E.L., et al. Highly sensitive thromboplastins do not improve INR precision. Am J Clin Pathol 109 3 (1998) 338-346
17. Testa S., Morstabilini G., Fattorini A., et al. Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system. Haematologica 87 12 (2002) 1265-1273
18. Coagulation Resource Committee C. CGL-A. Coagulation limited. Participant summary (2009) Northfield (IL): College of American Pathologists
19. Ng V.L. QC for the future: laboratory issues - POCT and POL concerns. Lab Med 36 10 (2005) 621-625
20. Ng V. My three wishes for point-of-care testing. Journal of Point-of-Care Testing 7 (2008) 99-101
21. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 Suppl (2008) 160S-198S
22. Oral Anticoagulation Monitoring Study Group. Point-of-care prothrombin time measurement for professional and patient self-testing use. A multicenter clinical experience. Oral Anticoagulation Monitoring Study Group. Am J Clin Pathol 115 2 (2001) 288-296
23. Tripodi A., Bressi C., Carpenedo M., et al. Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. Thromb Res 113 1 (2004) 35-40
24. Poller L., Keown M., Chauhan N., et al. European concerted action on anticoagulation: use of plasma samples to derive international sensitivity index for whole-blood prothrombin time monitors. Clin Chem 48 2 (2002) 255-260
25. Meijer P., Kluft C., Poller L., et al. A national field study of quality assessment of CoaguChek point-of-care testing prothrombin time monitors. Am J Clin Pathol 126 5 (2006) 756-761
26. Kitchen S., Kitchen D.P., Jennings I., et al. Point-of-care international normalised ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors. Thromb Haemost 96 5 (2006) 590-596
27. The Joint Commission. Standard QC.1.80 (2008), Joint Commission Resources, Oakbrook Terrace (IL)
28. College of American Pathologists. Point of care testing inspection checklist item POC.07568 (2007), College of American Pathologists, Northfield (IL)
29. Centers for Medicare and Medicaid Services. Centers for Disease Control and Prevention. 493.1253 Standard; Establishment and verification of method performance specifications. Available at:. http://wwwn.cdc.gov/clia/regs/subpart_k.aspx#493.1253 Accessed April 11, 2009
30. ISO 15189. Medical laboratories: particular requirements for quality and competence (2003), Standard 5.6.6 Switzerland: ISO (The International Organization for Standardization).
31. CLSI. C54-A. Verification of comparability of patient results within one health care system; approved guideline (2008), CLSI, Wayne (PA)
32. Sunderji R., Gin K., Shalansky K., et al. Clinical impact of point-of-care vs laboratory measurement of anticoagulation. Am J Clin Pathol 123 2 (2005) 184-188
33. Chapman D.C., Stephens M.A., Hamann G.L., et al. Accuracy, clinical correlation, and patient acceptance of two handheld prothrombin time monitoring devices in the ambulatory setting. Ann Pharmacother 33 7-8 (1999) 775-780
34. Shermock K.M., Bragg L., Connor J.T., et al. Differences in warfarin dosing decisions based on international normalized ratio measurements with two point-of-care testing devices and a reference laboratory measurement. Pharmacotherapy 22 11 (2002) 1397-1404
35. Kortke H., and Korfer R. International normalized ratio self-management after mechanical heart valve replacement: is an early start advantageous?. Ann Thorac Surg 72 1 (2001) 44-48
36. Menendez-Jandula B., Souto J.C., Oliver A., et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann Intern Med 142 1 (2005) 1-10
37. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 188S-203S
38. Weitz J.I., et al. Chapter 130. Anticoagulant and fibrinolytic drugs. In: Hoffman M., Benz Jr. E.J., Shattil S.J., et al. (Eds). Hematology: basic principles and practice. 4th edition (2005), Elsevier Churchill Livingstone, Philadlephia 2249-2267
39. In: Colman R.W., Clowes A.W., Marder V.J., et al. (Eds). Hemostasis and thrombosis: basic principles and clinical practice. 5th edition (2005), Lippincott Williams & Wilkins, Philadelphia
40. In: Greer J.P., Arber D.A., Rodgers G.M., et al. (Eds). Wintrobe's clinical hematology. 12th edition (2008), Lippincott Williams & Wilkins, Philadelphia
41. Laposata M., Green D., Van Cott E.M., et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122 9 (1998) 799-807
42. Papadopoulos S., Flynn J.D., and Lewis D.A. Fondaparinux as a treatment option for heparin-induced thrombocytopenia. Pharmacotherapy 27 6 (2007) 921-926
43. Lobo B., Finch C., Howard A., et al. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99 1 (2008) 208-214
44. Efird L.E., and Kockler D.R. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 40 7-8 (2006) 1383-1387
45. Hales S.C., Johnson G.S., and Wagner D. Comparison of six activated partial thromboplastin time reagents: intrinsic system factors' sensitivity and responsiveness. Clin Lab Sci 3 3 (1990) 194-196
46. van den Besselaar A.M., Neuteboom J., Meeuwisse-Braun J., et al. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin therapy. Clin Chem 43 7 (1997) 1215-1222
47. Kitchen S., Jennings I., Woods T.A., et al. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 49 1 (1996) 10-14
48. Eby C. Standardization of APTT reagents for heparin therapy monitoring: urgent or fading priority?. Clin Chem 43 7 (1997) 1105-1107
49. Olson J.D., Arkin C.F., Brandt J.T., et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 122 9 (1998) 782-798
50. Levine M.N., Hirsh J., Gent M., et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 154 1 (1994) 49-56
51. Brill-Edwards P., Ginsberg J.S., Johnston M., et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med 119 2 (1993) 104-109
52. CLSI. One-stage prothrombin time (PT) test and activated partial thromboplastin time (APTT) test. Approved guideline - second edition (2008), Clinical and Laboratory Standards Institute, Wayne (PA)
53. Ten Boekel E., and Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII: C. Pathophysiol Haemost Thromb 32 3 (2002) 137-142
54. Ten Boekel E., Bock M., Vrielink G.J., et al. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents. Thromb Res 121 3 (2007) 361-367
55. Raschke R.A., Guidry J.R., and Foley M.R. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol 96 5 Pt 2 (2000) 804-806
56. Rosborough T.K., and Shepherd M.E. Heparin resistance as detected with an antifactor Xa assay is not more common in venous thromboembolism than in other thromboembolic conditions. Pharmacotherapy 23 2 (2003) 142-146
57. Lehman C.M., Rettmann J.A., Wilson L.W., et al. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. Am J Clin Pathol 126 3 (2006) 416-421
58. Messori A., Vacca F., Vaiani M., et al. Antithrombin III in patients admitted to intensive care units: a multicenter observational study. Crit Care 6 5 (2002) 447-451
59. Kitchen S., Iampietro R., Woolley A.M., et al. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost 82 4 (1999) 1289-1293
60. Kitchen S., Theaker J., and Preston F.E. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 11 2 (2000) 137-144
61. Kovacs M.J., Keeney M., MacKinnon K., et al. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haematol 21 1 (1999) 55-60
62. Gosselin R.C., King J.H., Janatpour K.A., et al. Variability of plasma anti-Xa activities with different lots of enoxaparin. Ann Pharmacother 38 4 (2004) 563-568
63. McGlasson D.L. Using a single calibration curve with the anti-Xa chromogenic assay for monitoring heparin anticoagulation. Lab Med 36 5 (2005) 297-299
64. Robertson J.D., Brandao L., Williams S., et al. Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children. Thromb Res 122 6 (2008) 867-869
65. Spinler S.A., Wittkowsky A.K., Nutescu E.A., et al. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother 39 7-8 (2005) 1275-1285
66. Nichols J.H., Christenson R.H., Clarke W., et al. Executive summary. The National Academy of Clinical Biochemistry Laboratory Medicine Practice Guideline: evidence-based practice for point-of-care testing. Clin Chim Acta 379 1-2 (2007) 14-28 [discussion: 29-30]
67. Francis C.W. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program 2008 (2008) 259-265
68. Mueck W., Eriksson B.I., Bauer K.A., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47 3 (2008) 203-216
69. Kubitza D., Becka M., Voith B., et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78 4 (2005) 412-421
70. Tobu M., Iqbal O., Hoppensteadt D.A., et al. Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests. Clin Appl Thromb Hemost 8 4 (2002) 325-336
71. Greinacher A., and Warkentin T.E. The direct thrombin inhibitor hirudin. Thromb Haemost 99 5 (2008) 819-829
72. Warkentin T.E., Greinacher A., and Koster A. Bivalirudin. Thromb Haemost 99 5 (2008) 830-839
73. Tobu M., Iqbal O., Hoppensteadt D., et al. Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 10 4 (2004) 301-309
74. Tripodi A., Chantarangkul V., Arbini A.A., et al. Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemost 70 2 (1993) 286-288
75. Poller L. Standardization of the APTT test. Current status. Scand J Haematol Suppl 37 (1980) 49-63
76. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33 4 (2003) 173-183